Megan R Haymart1, Mousumi Banerjee, Huiying Yin, Francis Worden, Jennifer J Griggs. 1. Department of Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan; Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Because anaplastic thyroid cancer is a rare malignancy with a high mortality rate, the benefit of multimodality treatment was evaluated. METHODS: Overall survival was determined in the 2742 patients captured by the National Cancer Database who were diagnosed with anaplastic thyroid cancer between 1998 and 2008. Kaplan-Meier analysis and then Cox proportional hazard regression was performed, controlling for patient characteristics and treatment. RESULTS: Only older age (adjusted hazard ratio [AHR] for ≥ 85 years = 3.43, 95% confidence interval [CI] = 2.34-5.03; for 75-84 years, AHR = 2.85, 95% CI = 1.97-4.11; for 65-74 years, AHR = 2.20, 95% CI = 1.53-3.15; for 45-64 years, AHR = 2.08, 95% CI = 1.47-2.95) and omission of treatment were associated with greater mortality (omission of surgery: AHR = 1.79, 95% CI = 1.61-1.99; omission of radiation therapy: AHR = 1.56; 95% CI = 1.41-1.73; and omission of chemotherapy: AHR = 1.28, 95% CI = 1.15-1.43). In subgroup analysis of patients with American Joint Committee on Cancer stage IVA, IVB, and IVC anaplastic thyroid cancer, combination therapy with surgery, radiation, and chemotherapy was associated a difference in median survival of months. CONCLUSIONS: Multimodality management of anaplastic thyroid cancer results in a marginal treatment benefit. The poor overall survival of all anaplastic thyroid cancer patients, regardless of treatment, emphasizes the need for informed patients whose preferences are incorporated into treatment decision-making.
BACKGROUND: Because anaplastic thyroid cancer is a rare malignancy with a high mortality rate, the benefit of multimodality treatment was evaluated. METHODS: Overall survival was determined in the 2742 patients captured by the National Cancer Database who were diagnosed with anaplastic thyroid cancer between 1998 and 2008. Kaplan-Meier analysis and then Cox proportional hazard regression was performed, controlling for patient characteristics and treatment. RESULTS: Only older age (adjusted hazard ratio [AHR] for ≥ 85 years = 3.43, 95% confidence interval [CI] = 2.34-5.03; for 75-84 years, AHR = 2.85, 95% CI = 1.97-4.11; for 65-74 years, AHR = 2.20, 95% CI = 1.53-3.15; for 45-64 years, AHR = 2.08, 95% CI = 1.47-2.95) and omission of treatment were associated with greater mortality (omission of surgery: AHR = 1.79, 95% CI = 1.61-1.99; omission of radiation therapy: AHR = 1.56; 95% CI = 1.41-1.73; and omission of chemotherapy: AHR = 1.28, 95% CI = 1.15-1.43). In subgroup analysis of patients with American Joint Committee on Cancer stage IVA, IVB, and IVC anaplastic thyroid cancer, combination therapy with surgery, radiation, and chemotherapy was associated a difference in median survival of months. CONCLUSIONS: Multimodality management of anaplastic thyroid cancer results in a marginal treatment benefit. The poor overall survival of all anaplastic thyroid cancerpatients, regardless of treatment, emphasizes the need for informed patients whose preferences are incorporated into treatment decision-making.
Authors: Eric J Sherman; Su Hsien Lim; Alan L Ho; Ronald A Ghossein; Matthew G Fury; Ashok R Shaha; Michael Rivera; Oscar Lin; Suzanne Wolden; Nancy Y Lee; David G Pfister Journal: Radiother Oncol Date: 2011-10-06 Impact factor: 6.280
Authors: P I Haigh; P H Ituarte; H S Wu; P A Treseler; M D Posner; J M Quivey; Q Y Duh; O H Clark Journal: Cancer Date: 2001-06-15 Impact factor: 6.860
Authors: B McIver; I D Hay; D F Giuffrida; C E Dvorak; C S Grant; G B Thompson; J A van Heerden; J R Goellner Journal: Surgery Date: 2001-12 Impact factor: 3.982
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle Journal: Thyroid Date: 2012-11 Impact factor: 6.568
Authors: J Tennvall; G Lundell; P Wahlberg; A Bergenfelz; L Grimelius; M Akerman; A-L Hjelm Skog; G Wallin Journal: Br J Cancer Date: 2002-06-17 Impact factor: 7.640
Authors: Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak Journal: Ann Surg Oncol Date: 2021-05-25 Impact factor: 5.344
Authors: Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn Journal: Cancer Date: 2016-12-27 Impact factor: 6.860
Authors: H Vulpe; J Y Y Kwan; A McNiven; J D Brierley; R Tsang; B Chan; D P Goldstein; L W Le; A Hope; M Giuliani Journal: Curr Oncol Date: 2017-06-27 Impact factor: 3.677
Authors: Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins Journal: Head Neck Date: 2019-12-16 Impact factor: 3.147
Authors: Vlad C Sandulache; Michelle D Williams; Stephen Y Lai; Charles Lu; William N William; Naifa L Busaidy; Gilbert J Cote; Rajesh R Singh; Rajyalakshmi Luthra; Maria E Cabanillas Journal: Thyroid Date: 2016-11-29 Impact factor: 6.568
Authors: Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer Journal: Eur Arch Otorhinolaryngol Date: 2020-02-14 Impact factor: 2.503